{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T14:47:44Z","timestamp":1780325264626,"version":"3.54.1"},"reference-count":40,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Inner Mongolia Medical Academy Public Hospital Research Joint Fund Project","award":["2024GLLH1288"],"award-info":[{"award-number":["2024GLLH1288"]}]},{"name":"Independent Scientific Research Project of Ordos Central Hospital","award":["EY2024QN07"],"award-info":[{"award-number":["EY2024QN07"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Sage Open Medicine"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>Breakpoint Cluster Region (BCR)-Abelson tyrosine kinase (ABL) inhibitors are widely used in the treatment of blood cancers, particularly chronic myelogenous leukemia and are often combined with triazole antifungal agents to prevent fungal infections. However, the cardiac arrhythmia risks associated with BCR-ABL inhibitors in combination with triazole antifungal agents in real-world settings remain poorly understood. To address this gap, we conducted a pharmacovigilance study to evaluate and compare the cardiac arrhythmia profiles of BCR-ABL inhibitors when used with and without triazole antifungal agents in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A disproportionality analysis was performed using the Food and Drug Administration Adverse Event Reporting System database (2004Q1-2024Q2). To identify potential signals of cardiac arrhythmias associated with BCR-ABL inhibitors, with or without triazole antifungal agents, we calculated reporting odds ratios and 95% confidence intervals. Comparisons were made between BCR-ABL inhibitor monotherapy and all other drugs in the Food and Drug Administration Adverse Event Reporting System database, as well as between BCR-ABL inhibitors combined with triazole antifungal agents and BCR-ABL inhibitor monotherapy. Additionally, the Weibull shape parameter test was also used to evaluate time-to-onset.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      From 2004Q1 to 2024Q2, the Food and Drug Administration Adverse Event Reporting System database reported 21,433,114 cases, including 2666 and 68 cases of cardiac arrhythmias linked to BCR-ABL inhibitor monotherapy and its combination with triazole antifungal agents, respectively. The reporting odds ratios and their 95% confidence intervals for BCR-ABL inhibitor monotherapy, asciminib, nilotinib, and ponatinib were 1.31 (1.27\u20131.36), 2.11 (1.45\u20133.06), 2.66 (2.53\u20132.80), and 1.18 (1.05\u20131.33), respectively. Dasatinib plus triazole antifungal agents (reporting odds ratio: 2.98, 95% CI: 1.93\u20134.60) and ponatinib plus triazole antifungal agents (reporting odds ratio: 1.53, 95% CI: 1.08\u20132.16) were associated with a higher disproportionality of cardiac arrhythmias than BCR-ABL inhibitor monotherapy. The median time-to-onset was longer with monotherapy than with BCR-ABL inhibitors plus triazole antifungal agents (2.63 vs. 0.34\u2009months,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001), both indicating an early failure type.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>BCR-ABL inhibitors plus triazole antifungal agents increase the risk of cardiac arrhythmia, particularly in the early stages of treatment, with the risk decreasing over time.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20503121251328762","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T15:27:55Z","timestamp":1742916475000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Cardiac arrhythmias of BCR-ABL inhibitors with or without triazole antifungal agents: A real-world pharmacovigilance study based on the food and drug administration adverse event reporting system database"],"prefix":"10.1177","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7499-1669","authenticated-orcid":false,"given":"Peitao","family":"Xie","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Inner Mongolia Medical University Ordos School of Clinical Medicine, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lishan","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Inner Mongolia Medical University Ordos School of Clinical Medicine, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Scientific Education, The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Inner Mongolia Medical University Ordos School of Clinical Medicine, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Inner Mongolia Medical University Ordos School of Clinical Medicine, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pu","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Inner Mongolia Medical University Ordos School of Clinical Medicine, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0624-2"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.03.006"},{"issue":"17","key":"e_1_3_4_4_2","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.2174\/0929867328666211012093423","article-title":"Research status, synthesis and clinical application of recently marketed and clinical BCR-ABL inhibitors","volume":"29","author":"Xu XL","year":"2022","unstructured":"Xu XL, Cao YJ, Zhang W, et al. Research status, synthesis and clinical application of recently marketed and clinical BCR-ABL inhibitors. Curr Med Chem 2022; 29(17): 3050\u20133078.","journal-title":"Curr Med Chem"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01662-3"},{"issue":"1","key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-020-00905-2","article-title":"Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions","volume":"13","author":"Samra B","year":"2020","unstructured":"Samra B, Jabbour E, Ravandi F, et al. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. J Hematol Oncol 2020; 13(1): 70.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"e_1_3_4_7_2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(03)00979-3","article-title":"Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias","volume":"4","author":"Gambacorti-Passerini CB","year":"2003","unstructured":"Gambacorti-Passerini CB, Gunby RH, Piazza R, et al. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003; 4(2): 75\u201385.","journal-title":"Lancet Oncol"},{"issue":"7","key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00535-008-2200-y","article-title":"Gastrointestinal stromal tumors: past, present, and future","volume":"43","author":"Kitamura Y.","year":"2008","unstructured":"Kitamura Y. Gastrointestinal stromal tumors: past, present, and future. J Gastroenterol 2008; 43(7): 499\u2013508.","journal-title":"J Gastroenterol"},{"issue":"10","key":"e_1_3_4_9_2","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/phar.2850","article-title":"Utility of triazole antifungal therapeutic drug monitoring: insights from the Society of Infectious Diseases Pharmacists: endorsed by the Mycoses Study Group Education and Research Consortium","volume":"43","author":"McCreary EK","year":"2023","unstructured":"McCreary EK, Davis MR, Narayanan N, et al. Utility of triazole antifungal therapeutic drug monitoring: insights from the Society of Infectious Diseases Pharmacists: endorsed by the Mycoses Study Group Education and Research Consortium. Pharmacotherapy 2023; 43(10): 1043\u20131050.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"e_1_3_4_10_2","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(21)00232-5","article-title":"Management of drug-drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs","volume":"9","author":"Br\u00fcggemann RJ","year":"2022","unstructured":"Br\u00fcggemann RJ, Verheggen R, Boerrigter E, et al. Management of drug-drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs. Lancet Haematol 2022; 9(1): e58\u2013e72.","journal-title":"Lancet Haematol"},{"issue":"7","key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1200\/JCO.23.00897","article-title":"Bosutinib in resistant and intolerant pediatric patients with chronic phase chronic myeloid leukemia: results from the phase I part of study ITCC054\/COG AAML1921","volume":"42","author":"Brivio E","year":"2024","unstructured":"Brivio E, Pennesi E, Willemse ME, et al. Bosutinib in resistant and intolerant pediatric patients with chronic phase chronic myeloid leukemia: results from the phase I part of study ITCC054\/COG AAML1921. J Clin Oncol 2024; 42(7): 821\u2013831.","journal-title":"J Clin Oncol"},{"issue":"21","key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1001\/jama.2024.4783","article-title":"Ponatinib versus imatinib in frontline Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial","volume":"331","author":"Jabbour E","year":"2024","unstructured":"Jabbour E, Kantarjian HM, Aldoss I, et al. Ponatinib versus imatinib in frontline Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial. JAMA 2024; 331(21): 1814\u20131823.","journal-title":"JAMA"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400858"},{"issue":"7","key":"e_1_3_4_14_2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.20165","article-title":"Comparison of hepatotoxicity associated with new BCR-ABL tyrosine kinase inhibitors vs imatinib among patients with chronic myeloid leukemia: a systematic review and meta-analysis","volume":"4","author":"Wang Z","year":"2021","unstructured":"Wang Z, Wang X, Wang Z, et al. Comparison of hepatotoxicity associated with new BCR-ABL tyrosine kinase inhibitors vs imatinib among patients with chronic myeloid leukemia: a systematic review and meta-analysis. JAMA Netw Open 2021; 4(7): e2120165.","journal-title":"JAMA Netw Open"},{"key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-3-030-71913-5_6","volume-title":"Chronic myeloid leukemia","author":"Rea D.","year":"2021","unstructured":"Rea D. Adverse events associated with ATP-competitive BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia. In: Hehlmann R (eds). Chronic myeloid leukemia. Cham: Springer, 2021, pp. 77\u201391."},{"issue":"4","key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"E66","DOI":"10.1002\/ajh.23938","article-title":"Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: data from the FDA Adverse Event Reporting System","volume":"90","author":"Cortes J","year":"2015","unstructured":"Cortes J, Mauro M, Steegmann JL, et al. Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: data from the FDA Adverse Event Reporting System. Am J Hematol 2015; 90(4): E66\u2013E72.","journal-title":"Am J Hematol"},{"issue":"1","key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40360-024-00741-x","article-title":"Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system","volume":"25","author":"Zhao D","year":"2024","unstructured":"Zhao D, Long X, Wang J. Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system. BMC Pharmacol Toxicol 2024; 25(1): 20.","journal-title":"BMC Pharmacol Toxicol"},{"key":"e_1_3_4_18_2","unstructured":"United States of America: U.S. Food and Drug Administration. FDA Adverse Event Reporting System (FAERS): latest quarterly data files https:\/\/www.fda.gov\/drugs\/fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-latest-quarterly-data-files (2018 accessed 10 August 2024)."},{"issue":"7","key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s40264-014-0187-2","article-title":"Performance of the standardized MedDRA\u00ae queries for case retrieval in the French spontaneous reporting database","volume":"37","author":"G\u00e9niaux H","year":"2014","unstructured":"G\u00e9niaux H, Assaf D, Miremont-Salam\u00e9 G, et al. Performance of the standardized MedDRA\u00ae queries for case retrieval in the French spontaneous reporting database. Drug Saf 2014; 37(7): 537\u2013542.","journal-title":"Drug Saf"},{"key":"e_1_3_4_20_2","unstructured":"The International Council for harmonization of technical requirements for pharmaceuticals for human use. International Council for Harmonization. Introductory Guide for Standardized MedDRA Queries (SMQs) Version 27.1 https:\/\/admin.meddra.org\/sites\/default\/files\/guidance\/file\/SMQ_intguide_27_1_English.pdf (2024 accessed 13 August 2024)."},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.996179"},{"issue":"4","key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s40264-016-0503-0","article-title":"Signal detection based on time to onset algorithm in spontaneous reporting system of China","volume":"40","author":"Zhang T","year":"2017","unstructured":"Zhang T, Ye X, Guo X, et al. Signal detection based on time to onset algorithm in spontaneous reporting system of China. Drug Saf 2017; 40(4): 343\u2013350.","journal-title":"Drug Saf"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-84628-288-1_3"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.07.006"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-024-01421-9"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-024-01423-7"},{"issue":"1","key":"e_1_3_4_27_2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jaccao.2021.01.009","article-title":"Oncotherapeutic protein kinase inhibitors associated with pro-arrhythmic liability","volume":"3","author":"Ye JZ","year":"2021","unstructured":"Ye JZ, Hansen FB, Mills RW, et al. Oncotherapeutic protein kinase inhibitors associated with pro-arrhythmic liability. JACC CardioOncol 2021; 3(1): 88\u201397.","journal-title":"JACC CardioOncol"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1159\/000540542"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040826"},{"issue":"11","key":"e_1_3_4_30_2","doi-asserted-by":"crossref","first-page":"4582","DOI":"10.1182\/blood.V110.11.4582.4582","article-title":"In vitro cardiotoxicity potential comparative assessments of chronic myelogenous leukemia tyrosine kinase inhibitor therapies: dasatinib, imatinib and nilotinib","volume":"110","author":"Freebern WJ","year":"2007","unstructured":"Freebern WJ, Fang HS, Slade MD, et al. In vitro cardiotoxicity potential comparative assessments of chronic myelogenous leukemia tyrosine kinase inhibitor therapies: dasatinib, imatinib and nilotinib. Blood 2007; 110(11): 4582.","journal-title":"Blood"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01111-2"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70201-7"},{"issue":"4","key":"e_1_3_4_33_2","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/ehjcvp\/pvaa037","article-title":"Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database","volume":"7","author":"Alexandre J","year":"2021","unstructured":"Alexandre J, Salem JE, Moslehi J, et al. Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database. Eur Heart J Cardiovasc Pharmacother 2021; 7(4): 312\u2013320.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"6","key":"e_1_3_4_34_2","article-title":"Epidemiology of invasive fungal diseases among patients with haematological disorders in the Asia-Pacific: a prospective observational study","volume":"21","author":"Hsu LY","year":"2015","unstructured":"Hsu LY, Lee DG, Yeh SP, et al. Epidemiology of invasive fungal diseases among patients with haematological disorders in the Asia-Pacific: a prospective observational study. Clin Microbiol Infect 2015; 21(6): 594.e7\u2013594.e11.","journal-title":"Clin Microbiol Infect"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.01.002"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ1194"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2016.02.051"},{"issue":"18","key":"e_1_3_4_38_2","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.2165\/11596540-000000000-00000","article-title":"Triazole antifungal agents in invasive fungal infections: a comparative review","volume":"71","author":"Lass-Fl\u00f6rl C.","year":"2011","unstructured":"Lass-Fl\u00f6rl C. Triazole antifungal agents in invasive fungal infections: a comparative review. Drugs 2011; 71(18): 2405\u20132419.","journal-title":"Drugs"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2010.10.010"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.28.1813"},{"issue":"1","key":"e_1_3_4_41_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4062\/biomolther.2021.102","article-title":"Inhibition of cytochrome P450 enzymes by drugs-molecular basis and practical applications","volume":"30","author":"Guengerich FP.","year":"2022","unstructured":"Guengerich FP. Inhibition of cytochrome P450 enzymes by drugs-molecular basis and practical applications. Biomol Ther (Seoul) 2022; 30(1): 1\u201318.","journal-title":"Biomol Ther (Seoul)"}],"container-title":["Sage Open Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20503121251328762","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20503121251328762","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20503121251328762","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:30:14Z","timestamp":1777595414000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20503121251328762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":40,"alternative-id":["10.1177\/20503121251328762"],"URL":"https:\/\/doi.org\/10.1177\/20503121251328762","relation":{},"ISSN":["2050-3121","2050-3121"],"issn-type":[{"value":"2050-3121","type":"print"},{"value":"2050-3121","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"article-number":"20503121251328762"}}